Form DEF 14A Emergent BioSolutions streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
ACCESSWIRE
Advancing Dyadic s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial
Goal of validating that C1 produced proteins are safe in humans and to accelerate adoption and use of C1 technology platform for the development and manufacture of vaccines and therapeutics
Goal of bringing larger quantities of lower cost COVID-19 vaccines that can be used as a prime and booster to existing vaccines
Engaged CR2O to manage and support further preclinical and clinical development
Initiated toxicology study
cGMP manufacturing run in progress
Collaborating on next-generation COVID-19 variant vaccines and/or boosters through Korea and Southeast Asia vaccine development partnership with Medytox (
April 22, 2021
published at 12:30 PMglobenewswire
Dyadic International Hosting a Fireside Chat on “The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges”
Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time
GlobeNewswire
April 22, 2021
JUPITER, Fla., April 22, 2021 (GLOBE NEWSWIRE) Dyadic International, Inc. ( Dyadic , we , us , our , or the Company ) (NASDAQ:DYAI), a global biotechnology company focused on developing and deploying its proprietary C1-cell protein production platform to optimize the development of vaccines, therapeutics and other protein based products today announced that it will host a fireside chat on Tuesday, May 4, 2021 at 10:00am Eastern Time. The fireside chat will focus on the potential of the transformative Dyadic C1 protein technology in helping meet global health challenges.
Share:
JUPITER, Fla., April 22, 2021 (GLOBE NEWSWIRE) Dyadic International, Inc. ( Dyadic , we , us , our , or the Company ) (NASDAQ:DYAI), a global biotechnology company focused on developing and deploying its proprietary C1-cell protein production platform to optimize the development of vaccines, therapeutics and other protein based products today announced that it will host a fireside chat on Tuesday, May 4, 2021 at 10:00am Eastern Time. The fireside chat will focus on the potential of the transformative Dyadic C1 protein technology in helping meet global health challenges.
The moderated discussion will include the following Key Opinion Leaders (KOLs):
Alain Townsend, Ph.D. – Weatherall Institute - Oxford University